STOCKHOLM, March 13, 2026 /PRNewswire/ — On March 12, 2026, Ericsson (NASDAQ:ERIC) filed its Annual Report on Form 20-F for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission (SEC).

The Annual Report is available on Ericsson’s website at https://www.ericsson.com/en/investors. Shareholders may request a hard copy of the Annual Report by contacting the company.

NOTES TO EDITORS:

FOLLOW US:

Subscribe to Ericsson press releases here
Subscribe to Ericsson blog posts here
https://twitter.com/ericsson
https://www.facebook.com/ericsson
https://www.linkedin.com/company/ericsson

MORE INFORMATION AT:
Ericsson Newsroom
media.relations@ericsson.com  (+46 10 719 69 92)
investor.relations@ericsson.com  (+46 10 719 00 00)

ABOUT ERICSSON:
Ericsson’s high-performing networks provide connectivity for billions of people every day. For 150 years, we’ve been pioneers in creating technology for communication. We offer mobile communication and connectivity solutions for service providers and enterprises. Together with our customers and partners, we make the digital world of tomorrow a reality. www.ericsson.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/ericsson/r/ericsson-annual-report-on-form-20-f-filed-with-the-sec,c4317867

The following files are available for download:

https://mb.cision.com/Main/15448/4317867/3969640.pdf

Ericsson Annual Report on Form 20-F filed with the SEC

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

Jianzhi Education Technology Announces Agreement with SeaArt AI, One of the World's Top 20 Generative AI Platforms

BEIJING, June 1, 2026 /PRNewswire/ — Jianzhi Education Technology Group Company Limited (the…

Reinvented & Upgraded: Kuailu AI CRM into the 2.0 Era

HONG KONG, Sept. 10, 2026 /PRNewswire/ — Industry research reveals that 68% of…

Piramal Pharma Solutions and NP2 to Complete Cyclophosphamide Development Phase Next Month

Piramal and NP2 are set to complete the drug development phase of…